相关实验视频

Updated: Jul 15, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

持久的机械循环支持:JACC科学声明

Ryan J Tedford¹, Marzia Leacche², Angela Lorts³

¹Medical University of South Carolina, Charleston, South Carolina, USA.

Journal of the American College of Cardiology

|September 27, 2023

概括

耐用左心室辅助器件 (dLVADs) 为晚期心力衰竭患者提供了更好的生存率,在5年内接近60%. 然而,诸如推迟转诊等挑战阻碍了这一关键疗法的更广泛采用.

科学领域:

心脏病学心脏病学
医疗器械医疗器械
心脏衰竭管理的管理

背景情况:

晚期心力衰竭 (HF) 仅仅通过医疗治疗就有不良预后.
耐用左心室辅助装置 (dLVAD) 是高级高频率患者的关键选择.
最近的dLVAD创新已经改善了安全性和患者存活率.

研究的目的:

审查与dLVAD治疗相关的当代结果和挑战.
突出dLVADs作为桥梁移植或目的地治疗的潜力.
讨论新兴的dLVAD技术.

主要方法:

关于dLVAD技术和患者结果的当前文献的综述.
对生存率和不良事件概况的分析.
讨论临床采用障碍和未来的设备开发.

主要成果:

dLVAD的支持显示,5年生存率接近60%,相当于心脏移植2年.
随着技术的进步,血栓,中风和出血等不良事件已经减少.
采用dLVAD的重大障碍包括患者推迟转诊以及临床医生对结果和生活质量益处的认识不足.

结论:

对于晚期心力衰竭患者,dLVAD疗法提供了显著的生存益处.
解决转诊障碍和提高临床医生的知识对于更广泛的dLVAD采用至关重要.
新的,不那么侵入性的dLVAD技术正在开发中,有望进一步改进.

关键词:

心脏衰竭是因为心脏衰竭.心脏移植心脏移植手术左心室辅助装置的使用机械循环支持机械循环支持

更多相关视频

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

相关概念视频

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...